ABSTRACT High titers of antibodies to anti thyrotropin receptor ( TRA-Ab), and thyroperoxidase (TPO-Ab) 
Introduction:
Graves' disease (GD) is an autoimmune disorder characterized in its typical presentation by the unique association of thyrotoxicosis, goiter and ophthalmopathy (1) . The exact etiology of GD is overall still unknown. However, the majority of investigators share the concept that GD is a multifactorial disease caused by a complex interaction between genetic and environmental factors that lead to the loss of immune tolerance to thyroid antigens, and therefore to the initiation of an immune reaction against the thyroid (2).
GD is one of the most frequent diseases among autoimmune disorders, with an annual incidence of approximately 14 per 100,000 (3) . In iodine sufficient areas, it accounts for 70-80% of all cases of thyrotoxicosis (4) . As in most autoimmune diseases, GD is more frequent in women than in men, with a ratio of approximately 5/1. GD can be observed at any age, including childhood, although its incidence peaks between the fifth and sixth decades (5) .
Ethnical differences in the incidence of GD have not been investigated consistently, although there seems to be a higher prevalence of the disease in Caucasians and Asians than in Africans (6) . Graves (GD) disease is caused by circulating antibodies that mimic the action of the thyroid stimulating hormone (TSH), namely binding to and activating its receptor (TSHR), resulting in increased synthesis and release of thyroid hormones (hyperthyroidism) and hypertrophy of thyroid follicular cells (goiter). Ophthalmopathy, the most common extra thyroidal feature of GD, is clinically present in about 50% of patients, and, although its pathogenesis remains to be completely elucidated, it is believed to be due to an autoimmune reaction against antigens shared by the thyroid and orbital tissues, among which the TSHR is the most reasonable candidate (1) . Thyrotropin receptor antibody (TRAb) is a well known marker of thyroid gland autoimmunity and may have some predictive value in the recurrence of Graves' disease after treatment with antithyroid drugs (7) . Anti-thyroid peroxidase antibody (anti-TPO) is important in diagnosing autoimmune thyroid disease and for judging treatment efficacy (8) . Anti-TPO is also found in sera of about 10% of normal adults, with an increasing prevalence (up to 30%) in older adults (9) . More patients with thyroiditis have high serum anti-TPO than anti-Thyroglobin antibody concentrations (10) .
Materials and methods:
One hundred Sudanese patients with hyperthyroidism (50with hyperthyroidism and clinically diagnosed with graves' disease, 50 with hyperthyroidism and clinically without graves' disease), and fifty apparently healthy as control group , age and sex were matched.
Study done in Endocrinology Outpatient Clinic at Omdurman Teaching Hospital, Khartoum state, Sudan, during the period June 2011 to June 2013. An informed consent procedure was approved by the local medical authority, and all patients were informed about the purpose of the study. Venous blood samples(5mL)were taken from each participant by using disposable syringe. The blood samples allowed to clot for 20 minutes at room temperature and then serum was obtained after centrifugation at 300rpms. Thyroid function test ( FT3, FT4, and TSH) was determined by using fully automated chemical analyzer (ROCH ELECSYS ) and COBAS kits, and, anti Thyroperoxidase antibodies (TPO-Ab), and anti thyrotropin receptor antibodies (TRA-Ab) were determined by ELISA technique with Euro immune Kits.
Results:
The mean age of patients with hyperthyroidism without graves' disease was (33.22±10.04 years), while the mean age of patient with graves' disease was 34.82±11.13 years, and control group was (34.82±11.13)years, p. value 0.394. The (14.5-35 .5 U/L), positive(more than 35.5 U/L) for anti-TPO, and negative (less than1 U/L), Equivocal (1-2 U/L), positive(more than 2 U/L) for anti-TRA. Fig 1: shows correlation between serum titter of TRA antibodies and serum FT3 among Sudanese patients with Graves disease. Significant positive correlation (p= 0.0115, r=0.34) Discussion: Over the past five decades, improvements in the sensitivity and specificity of thyroid test methodologies have dramatically impacted the clinical strategies for detecting and treating thyroid disorders (11) .
ReseaRch PaPeR
The mean age at onset of hyperthyroidism disease was 34.8± 11.13 years with range 18-59 years ,This finding is in agreement with those reported by Biassoni et al (12) . In the patients with graves' disease study showed there were significant increase in mean of FT3, FT4, and significant decrease in mean of TSH compared with control group,This indicate that the laboratory hallmark of graves is the finding elevated levels of serum thyroxine (T4) and triiodothyronine (T3), associated with undetectable serum TSH. Because total T4 and T3 measurements are influenced by multiple conditions affecting serum thyroxine-binding globulin (TBG) (13) , free thyroid hormone (free T4 (FT4) and free T3 (FT3) measurement, is nowadays considered the gold standard for the diagnosis of thyrotoxicosis.TSH is the initial screening test in the evaluation of a suspected thyrotoxicosis, but it is strongly recommended to add measurement of FT4 to improve diagnostic accuracy (14) . Antibodies against the TSH receptor (TRAbs) are pathognomonic for graves' disease, our study showed significant increase in mean of TRA in patients with graves when compared with both patients with hyperthyroidism and control group. TRA was detected in 90% of patients with graves' disease, and undetected among control group in this study. They are detectable in the serum of about 98% of untreated GD patients using a second generation assay (15) and in an even higher proportion of patients using a third generation assay (16) . TRA-Ab measurement is a very valuable tool in the differential diagnosis between GD and thyrotoxicosis due to other causes, and, the detection of TRA-Abs rules out other causes of thyrotoxicosis (17) . However,TRA-Ab measurement is required when the clinical picture is not clear (18) .
Serum anti-thyroid peroxidase (TPO) was significant increase in patients with graves, when compared with both hyperthyroidism and control group, 16% of patients with graves had a positive in this study. Other study in Sudan shows 66.7% of the graves patient have positive TPO (18) .Serum anti-thyroid peroxidase antibodies (TPO), although detectable on the majority of GD patients, is generally not useful for GD diagnosis (19) . Our recommendation, importance of screening for anti TRA-Ab, TPO-Ab in non-autoimmune thyroid disorders. TRA antibodies is best laboratory maker in diagnoses of Graves disease, it can make the diagnosis almost unmistakable.
